Experimental hyperhomocysteinemia reduces bone quality in rats.
Markus Herrmann1, Britt Wildemann, Lutz Claes
1Department of Clinical Chemistry and Laboratory Medicine, University Hospital of Saarland, Homburg/Saar, Germany.
Clinical Chemistry
|June 26, 2007
Summary
Hyperhomocysteinemia (HHCY) significantly weakens bone quality and increases fragility in rats. This study provides evidence that elevated homocysteine is a direct cause of osteoporosis.
Area of Science:
- Biomedical research
- Bone biology
- Metabolic disorders
Background:
- Hyperhomocysteinemia (HHCY) is a potential risk factor for osteoporosis.
- This study investigates the causal role of HHCY in osteoporosis development in vivo.
Purpose of the Study:
- To determine if elevated homocysteine levels cause osteoporosis.
- To assess the impact of HHCY on bone fragility and microarchitecture.
Main Methods:
- Rats were divided into control, moderate HHCY (methionine-enriched diet), and intermediate HHCY (homocystine-enriched diet) groups.
- Bone fragility (axial compression test), bone area (histomorphometry), and bone turnover markers (osteocalcin, CTx) were measured.
Main Results:
- HHCY significantly increased bone fragility and decreased bone area in the femur and lumbar spine.
- Bone formation marker osteocalcin decreased, while bone resorption marker CTx showed no significant difference.
- Methionine-fed rats showed an 18% increase in bone fragility, while homocystine-fed rats showed a 36% increase.
Conclusions:
- Increased circulating homocysteine consistently reduces bone quality.
- The findings strongly suggest that HHCY is a causal factor in osteoporosis.
